The interplay of factors in metabolic syndrome: understanding its roots and complexity
Conclusion: Cinchonine, a potential oral small-molecule GLP-1R agonist, could reduce blood glucose and ameliorate NASH, providing a strategy for developing small-molecule GLP-1R agonists
Liver issues are uncommon on GLP-1s, but contact your healthcare provider if you notice persistent fatigue beyond typical medication adjustment, upper right abdominal discomfort, dark urine or pale stools, yellowing of the skin or eyes, or nausea that worsens rather than improves over time
They can affect ~8% of patients and may result in drug discontinuation [108]
Move from 10 mg to 7.5 mg for 6 weeks, then 7.5 mg to 5 mg for 6 weeks, then 5 mg to 2.5 mg for 6 weeks before complete discontinuation